Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 385, Issue 9965, 2015, Pages 341-350

  Raal, Frederick J ^a   Honarpour, Narimon ^b   Blom, Dirk J ^c   Hovingh, G Kees ^d   Xu, Feng ^b   Scott, Rob ^b   Wasserman, Scott M ^b   Stein, Evan A ^e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; ROSUVASTATIN; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GASTROENTERITIS; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA; HUMAN; INFLUENZA; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; MALE; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCREENING TEST; SIDE EFFECT; ULTRACENTRIFUGATION; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921459685     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61374-X     Document Type: Article

References (32)

1. M Cuchel, E Bruckert, HN Ginsberg et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society Eur Heart J 2014 10.1093/eurheartj/ehu274 published online July 22.
2. E Usifo, SE Leigh, RA Whittall et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment Ann Hum Genet 76 2012 387 401
3. B Sjouke, DM Kusters, I Kindt et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome Eur Heart J 2014 10.1093/eurheartj/ehu058 published online Feb 28.
4. HH Hobbs, MS Brown, JL Goldstein Molecular genetics of the LDL receptor gene in familial hypercholesterolemia Hum Mut 1 1992 445 466
5. FJ Raal, RD Santos Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment Atherosclerosis 223 2012 262 268
6. AD Marais, FJ Raal, EA Stein et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia Atherosclerosis 197 2008 400 406
7. FJ Raal, GJ Pilcher, DR Illingworth et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia Atherosclerosis 135 1997 249 256
8. C Gagne, D Gaudet, E Bruckert the Ezetimibe Study group Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia Circulation 105 2002 2469 2475
9. FDA news release FDA approves new orphan drug for rare cholesterol disorder http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm Dec 26, 2012 (accessed May 28, 2014).
10. FDA news release FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337195.htm Jan 29, 2013 (accessed May 28, 2014).
11. GR Thompson for the HEART-UK LDL Apheresis Working Group Recommendations for the use of LDL apheresis Atherosclerosis 198 2008 247 255
12. F Raal, R Scott, R Somaratne et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
13. EA Stein, N Honarpour, SM Wasserman, F Xu, R Scott, FJ Raal Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120
14. EA Stein, T Turner, N Pluncket et al. Friedewald formula significantly underestimates LDL cholesterol compared to preparative ultracentrifugation below 70 mg/dL leading to over estimation of the LDL cholesterol reduction for new drugs in development J Am Coll Cardiol 63 12-S 2014 abstr 1259-145.
15. FJ Raal, RD Santos, DJ Blom et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
16. DJ Rader, JJ Kastelein Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia Circulation 129 2014 1022 1032
17. M Cuchel, EA Meagher, H du Toit Theron et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 2013 40 46
18. MJ Koren, RP Giugliano, FJ Raal et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial Circulation 129 2014 234 243
19. DJ Blom, T Hala, M Bolognese et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
20. MJ Koren, P Lundqvist, M Bolognese et al. Anti-PCSK9 monotherapy for hypercholesterolemia. The MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2531 2540
21. JG Robinson, BS Nedergaard, WJ Rogers et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial JAMA 311 2014 1870 1882
22. E Stroes, D Colquhoun, D Sullivan et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
23. EA Stein, RP Giugliano, MJ Koren et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials Eur Heart J 2014 10.1093/eurheartj/ehu085 published online March 4.
24. FJ Raal, GJ Pilcher, VR Panz et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy Circulation 124 2011 2202 2207
25. S Bertolini, L Pisciotta, C Rabacchi et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy Atherosclerosis 227 2013 342 348
26. MH Davidson, EA Stein, CA Dujovne et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day Am J Cardiol 79 1997 38 42
27. J Pedro-Botet, EJ Schaefer, RG Bakker-Arkema et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner Atherosclerosis 158 2001 183 193
28. M Seed, F Hoppichler, D Reaveley et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia N Engl J Med 322 1990 1494 1499
29. HG Kraft, A Lingenhel, FJ Raal, M Hohenegger, G Utermann Lipoprotein(a) in homozygous familial hypercholesterolemia Arterioscler Thromb Vasc Biol 20 2000 522 528
30. FJ Raal, RP Giugliano, MS Sabatine et al. Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials J Am Coll Cardiol 63 2014 1278 1288
31. Trial assessing long term use of PCSK9 inhibition in subjects with genetic LDL disorders (TAUSSIG) http://clinicaltrials.gov/show/NCT01624142 (accessed Aug 9, 2014).
32. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) http://clinicaltrials.gov/ct2/show/NCT01764633 (accessed Aug 9, 2014).